Aptose Biosciences (APTO) 10-K 22 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 22, 2022	Jun. 30, 2021
Document Information [Line Items]
Entity Central Index Key	0000882361
Entity Registrant Name	Aptose Biosciences Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	001-3200
Entity Incorporation, State or Country Code	CA
Entity Tax Identification Number	98-1136802
Entity Address, Address Line One	251 Consumers Road, Suite 1105
Entity Address, City or Town	Toronto
Entity Address, State or Province	ON
Entity Address, Postal Zip Code	M2J 4R3
City Area Code	647
Local Phone Number	479-9828
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	APTO
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 293,330,791
Entity Common Stock, Shares Outstanding		92,229,189
Auditor Name	KPMG LLP
Auditor Location	Vaughan, Canada
Auditor Firm ID	85

Consolidated Statements of Fina

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 39,114	$ 117,393
Investments	40,014	5,000
Prepaid expenses	2,476	2,554
Other current assets	133	129
Total current assets	81,737	125,076
Non-current assets:
Property and equipment	323	261
Right-of-use assets, operating leases	465	925
Total non-current assets	788	1,186
Total assets	82,525	126,262
Current liabilities:
Accounts payable	1,699	2,171
Accrued liabilities	6,016	4,102
Current portion of lease liability, operating leases	459	539
Total current liabilities	8,174	6,812
Non-current liabilities:
Lease liability, operating leases	115	535
Total liabilities	8,289	7,347
Shareholders’ equity:
Common shares, no par value, unlimited authorized shares, 92,215,024 and 88,881,737 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively	437,386	429,523
Additional paid-in capital	63,673	50,861
Accumulated other comprehensive loss	(4,316)	(4,316)
Deficit	(422,507)	(357,153)
Total shareholders’ equity	74,236	118,915
Total liabilities and shareholders’ equity	$ 82,525	$ 126,262

Consolidated Statements of Fi_2

Consolidated Statements of Financial Position (Parentheticals) - $ / shares $ / shares in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Common shares, no par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized	Unlimited	Unlimited
Common shares, issued (in shares)	92,215,024	88,881,737
Common shares, outstanding (in shares)	92,215,024	88,881,737

Consolidated Statements of Loss

Consolidated Statements of Loss and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue	$ 0	$ 0
Expenses:
Research and development	45,985	29,288
General and administrative	19,462	26,480
Operating expenses	65,447	55,768
Other income :
Interest income	94	522
Foreign exchange gain/(loss)	(1)	8
Total other income	93	530
Net loss	(65,354)	(55,238)
Other comprehensive loss:
Unrealized loss on securities available-for-sale	0	(18)
Total comprehensive loss	$ (65,354)	$ (55,256)
Basic and diluted loss per common share (in dollars per share)	$ (0.73)	$ (0.67)
Weighted average number of common shares outstanding used in the calculation of (in thousands)
Basic and diluted loss per common share (in shares)	89,086	81,837

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands	The 2020 ATM Offering [Member]Common Stock [Member]	The 2020 ATM Offering [Member]Additional Paid-in Capital [Member]	The 2020 ATM Offering [Member]AOCI Attributable to Parent [Member]	The 2020 ATM Offering [Member]Retained Earnings [Member]	The 2020 ATM Offering [Member]	Public Offering [Member]Common Stock [Member]	Public Offering [Member]Additional Paid-in Capital [Member]	Public Offering [Member]AOCI Attributable to Parent [Member]	Public Offering [Member]Retained Earnings [Member]	Public Offering [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019											76,108,000
Balance at Dec. 31, 2019											$ 365,490	$ 34,649	$ (4,298)	$ (301,915)	$ 93,926
Common shares issued (in shares)						11,854,000
Common shares issued under the May 2020 ATM						$ 58,234	$ 0	$ 0	$ 0	$ 58,234
Common shares issued upon exercise of stock options (in shares)											235,000
Common shares issued upon exercise of stock options											$ 998	(425)	0	0	573
Stock-based compensation											0	21,438	0	0	21,438
Net loss											$ 0	0	0	(55,238)	(55,238)
Common shares issued upon redemption of restricted share units (in shares)											685,000
Common shares issued upon redemption of restricted share units											$ 4,801	(4,801)	0	0	0
Other comprehensive loss											$ 0	0	(18)	0	(18)
Balance (in shares) at Dec. 31, 2020											88,882,000
Balance at Dec. 31, 2020											$ 429,523	50,861	(4,316)	(357,153)	118,915
Common shares issued pursuant to the Hanmi licensing fees (in shares)											3,236,000
Common shares issued pursuant to the Hanmi licensing fees											$ 7,500	0	0	0	$ 7,500
Common shares issued (in shares)	15,000				15,315
Common shares issued under the May 2020 ATM	$ 36	$ 0	$ 0	$ 0	$ 36
Common shares issued upon exercise of stock options (in shares)											82,000				82,000
Common shares issued upon exercise of stock options											$ 327	(137)	0	0	$ 190
Stock-based compensation											0	12,949	0	0	12,949
Net loss											$ 0	0	0	(65,354)	(65,354)
Balance (in shares) at Dec. 31, 2021											92,215,000
Balance at Dec. 31, 2021											$ 437,386	$ 63,673	$ (4,316)	$ (422,507)	$ 74,236

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss for the year	$ (65,354)	$ (55,238)
Items not involving cash:
Stock-based compensation	12,949	21,438
Shares issued to Hanmi Pharmaceutical as license fees	7,500	0
Depreciation and amortization	150	152
Amortization of right-of-use assets	472	462
Interest on lease liabilities	43	69
Unrealized foreign exchange gain/(loss)	(7)	(8)
Accrued interest on investments	(18)	33
Change in operating working capital:
Prepaid expenses	78	(1,529)
Operating lease payments	(555)	(537)
Other assets	(4)	12
Accounts payable	(472)	211
Accrued liabilities	1,914	1,044
Cash used in operating activities	(43,304)	(33,891)
Cash flows from financing activities:
Offering costs paid	0	(168)
Issuance of common shares pursuant to exercise of stock options	190	573
Cash provided by financing activities	226	58,807
Cash flows from (used in) investing activities:
Maturity (acquisition) of investments, net	(34,996)	12,707
Purchase of property and equipment	(212)	(79)
Cash provided by (used in) investing activities	(35,208)	12,628
Effect of exchange rate fluctuations on cash and cash equivalents held	7	7
Increase/(decrease) in cash and cash equivalents	(78,279)	37,551
Cash and cash equivalents, beginning of year	117,393	79,842
Cash and cash equivalents, end of year	39,114	117,393
The 2020 ATM Offering [Member]
Cash flows from financing activities:
Issuance of common shares	36	0
Public Offering [Member]
Cash flows from financing activities:
Issuance of common shares	$ 0	$ 58,402

Note 1 - Reporting Entity

Note 1 - Reporting Entity	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Reporting entity: Aptose Biosciences Inc. (“Aptose” or the “Company”) is a clinical‑stage precision oncology company developing differentiated kinase inhibitors addressing unmet medical needs in oncology. The Company’s executive offices are located in San Diego, California and its head office is located in Toronto, Canada. Aptose has two third 806 1a/b, 1a/b November 2021, HM43239 HM43239 HM43239 FLT3, HM43239 1/2 HM43239 January 1, 2022. December 2021 253, 1a/b We are advancing first not 19 not Since our inception, we have financed our operations and technology acquisitions primarily from equity financing, proceeds from the exercise of warrants and stock options, and interest income on funds held for future investment. Our uses of cash for operating activities have primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices and laboratories, fees paid in connection with preclinical and clinical studies, drug manufacturing costs, laboratory supplies and materials, and professional fees. We do not We believe that our cash, cash equivalents and investments on hand at December 31, 2021 12 twelve may Our ability to raise additional funds could be affected by adverse market conditions, the status of our product pipeline, possible delays in enrollment in our trial related to COVID- 19, may not may

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Significant accounting policies (a) Basis of consolidation: These consolidated financial statements include the accounts of its subsidiaries. All intercompany transactions, balances, revenue and expenses are eliminated on consolidation. (b) Basis of presentation: These consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States, or GAAP and the rules and regulations of the Securities and Exchange Commission, or SEC, related to annual reports filed on Form 10 (c) Significant accounting policies, estimates and judgments: The preparation of the consolidated financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of revenue and expenses during the reporting period. Actual outcomes could differ from those estimates. The consolidated financial statements include estimates, which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements and may The estimates and underlying assumptions are reviewed on a regular basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected. (d) Leases The Company’s operating leases of tangible property with terms greater than twelve (e) Cash and cash equivalents: Cash and cash equivalents are short-term highly liquid investments with original maturities of 90 (f) Investments: Investments consist of term deposits with original maturities greater than 90 (g) Concentration of risk: The Company is subject to credit risk from the Company’s cash and cash equivalents and investments. The carrying amount of the financial assets represents the maximum credit exposure. The Company manages credit risk associated with its cash and cash equivalents and investments by maintaining minimum standards of R1‑low (h) Property and equipment: Property and equipment is measured at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. The Company records depreciation at rates that charge operations with the cost of the assets over their estimated useful lives on a straight‑line basis as follows: Office furniture 5 years Laboratory equipment 5 years Computer hardware 3 years Computer software 3 years Leasehold improvements Life of lease The residual value, useful life and methods of depreciation of the assets are reviewed at each reporting period and adjusted prospectively if appropriate. (i) Research and development: Research and development (R&D) costs are expensed as incurred. R&D costs consist primarily of salaries and benefits, stock-based compensation, manufacturing, contract services, clinical trials and research related overhead. Non-refundable advance payments for goods and services that will be used in future research are recorded in prepaid and other assets and are expensed when the services are performed. The Company records expenses for research and development activities based on Management’s estimates of services received and efforts expended pursuant to contracts with vendors that conduct research and development on the Company’s behalf. The financial terms vary from contract to contract and may (j) Fair value: The Company measures its financial assets and liabilities at fair value. The carrying amounts for the Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. (k) Stock-based compensation: The Company has a stock‑based compensation plan (the “Plan”) available to officers, directors, employees and consultants with grants under the Plan approved by the Company’s Board of Directors. Under the Plan, the exercise price of each option equals the closing trading price of the Company’s stock on the day prior to the grant if the grant is made during the trading day or the closing trading price on the day of grant if the grant is issued after markets have closed. Vesting is provided for at the discretion of the Board of Directors and the expiration of options is to be no 10 The Company uses the fair value based method of accounting for employee awards granted under the Plan. The Company calculates the fair value of each stock option grant using the Black‑Scholes option pricing model at the grant date. The stock‑based compensation cost of the options is recognized as stock‑based compensation expense over the relevant vesting period of the stock options using an estimate of the number of options that will eventually vest. Stock options awarded to non‑employees are measured at grant-date fair value of the equity instruments issued in accordance with FASB issued accounting standards update No 2018 07, 718. The Company has a stock incentive plan pursuant to which the Board may (l) Segment reporting: Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, or CODM. The Company’s Chief Executive Officer serves as its CODM. The Company views its operations and manages its business as one segment, which is the discovery and development of personalized therapies addressing unmet medical needs in oncology. The Company operates primarily in the US. (m) Loss per share: Basic loss per share is computed by dividing the net loss available to common shareholders by the weighted average number of shares outstanding during the year. Diluted loss per share is computed similarly to basic loss per share except that the weighted average share outstanding is increased to include additional shares for the assumed exercise of stock options and warrants, if dilutive. The number of additional shares is calculated by assuming that outstanding stock options and warrants were exercised and that the proceeds from such exercises were used to acquire common stock at the average market price during the year. The inclusion of the Company’s stock options and warrants in the computation of diluted loss per share has an anti‑dilutive effect on the loss per share and, therefore, they have been excluded from the calculation of diluted loss per share. (n) Income taxes: The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. Reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely than not December 31, 2021 December 31, 2020, not not

Note 3 - Cash and Cash Equivale

Note 3 - Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Cash and Cash Equivalents Disclosure [Text Block]	3. Cash and cash equivalents: Cash and cash equivalents consists of cash of $294 thousand ( December 31, 2020 90 December 31, 2020

Note 4 - Prepaid Expenses

Note 4 - Prepaid Expenses	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Prepaid Expenses [Text Block]	4. Prepaid expenses: December 31, December 31, 2021 2020 Prepaid research and development expenses $ 632 $ 622 Other prepaid expenses 1,844 1,932 $ 2,476 $ 2,554

Note 5 - Property and Equipment

Note 5 - Property and Equipment	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and equipment: December 31, 2021 Cost Accumulated depreciation Net book value Laboratory equipment $ 369 $ 188 $ 181 Computer hardware 198 144 54 Computer software 222 222 - Office furniture 140 95 45 Leasehold improvements 184 141 43 $ 1,113 $ 790 $ 323 December 31, 2020 Cost Accumulated depreciation Net book value Laboratory equipment $ 185 $ 177 $ 8 Computer hardware 170 99 71 Computer software 222 174 48 Office furniture 140 72 68 Leasehold improvements 184 118 66 $ 901 $ 640 $ 261

Note 6 - Right-of-use Assets, O

Note 6 - Right-of-use Assets, Operating Leases	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Right-of-use Assets Disclosure [Text Block]	6. Right-of-use assets, operating leases: Year ended Year ended Right-of-use assets, beginning of year $ 1,848 $ 1,837 Additions to right-of-use assets 12 11 Right-of-use assets, end of year 1,860 1,848 Accumulated amortization (1,395 ) (923 ) Right-of use assets, NBV $ 465 $ 925

Note 7 - Investments

Note 7 - Investments	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	7. Investments: Investments consisted of the following as of December 31, 2021 December 31, 2020: December 31, 2021 Cost Unrealized gain Market value Guaranteed Investment Certificate $ 20,016 - 20,016 Commercial notes 19,998 19,998 $ 40,014 - 40,014 December 31, 2020 Cost Unrealized gain Market value United States Treasury Bills $ 5,000 - 5,000 $ 5,000 - 5,000

Note 8 - Fair Value Measurement

Note 8 - Fair Value Measurements and Financial Instruments	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	8. Fair value measurements and financial instruments: The fair value hierarchy establishes three Level 1 Level 2 not Level 3 no The fair value hierarchy gives the highest priority to Level 1 3 The following table presents the fair value of the Company’s financial instruments for the periods presented: December 31, 2021 Level 1 Level 2 Level 3 Assets Money Market accounts $ 17,974 $ - $ 17,974 $ - Money Market Funds 15,801 - 15,801 - High interest savings accounts 5,045 - 5,045 - Commercial notes 19,998 - 19,998 - Guaranteed Investment Certificate 20,016 20,016 $ 78,834 $ - $ 78,834 $ - December 31, 2020 Level 1 Level 2 Level 3 Assets Money Market accounts $ 668 $ - $ 668 $ - Money Market Funds 44,000 - 44,000 - High interest savings accounts 48,397 - 48,397 - United States Treasury Bill 5,000 - 5,000 - Government of Canada Treasury Bill 23,999 - 23,999 - $ 122,064 $ - $ 122,064 $ -

Note 9 - Accrued Liabilities

Note 9 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	9. Accrued liabilities: Accrued liabilities as of December 31, 2021 December 31, 2020 December 31, December 31, 2021 2020 Accrued personnel related costs $ 2,152 $ 1,917 Accrued research and development expenses 3,520 1,932 Other accrued expenses 344 253 $ 6,016 $ 4,102

Note 10 - Lease Liability

Note 10 - Lease Liability	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	10. Lease liability Aptose leases office space and lab space in San Diego, California. The lease for the office space expires on March 31, 2023 February 28, 2022 twelve June 30, 2023 5 not Minimum payments, undiscounted, under our operating leases are as follows: Years ending December 31, 2022 $ 470 2023 123 Thereafter - $ 593 To calculate the lease liability, the lease payments in the table above were discounted over the remaining term of the leases using the Company’s incremental borrowing rate as at January 1, 2019 842, December 31, December 31, 2021 2020 Weighted-average remaining term – operating leases (years) 1.2 2.1 Weighted-average discount rate – operating leases 5.37 % 5.40 % Lease liability, current portion $ 459 $ 539 Lease liability, long term portion 115 535 Lease liability, total $ 574 $ 1,074 Operating lease costs and operating cash flows from our operating leases are as follows: Year ended December 31, 2021 Year ended December 31, 2020 Operating lease cost $ 515 $ 530 Operating cash flows from operating leases $ 555 $ 537

Note 11 - Share Capital

Note 11 - Share Capital	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Share capital: The Company has authorized share capital of an unlimited number of common voting shares. (a) Equity issuances: (i) On November 4, 2021, HM43239. December 14, 2021, five 5 (ii) 2020 On May 5, 2020, 2020 2020 may, December 31, 2021, (iii) July/August 2020 On July 20, 2020 August 10, 2020, (b) Loss per share: Loss per common share is calculated using the weighted average number of common shares outstanding and is presented in the table below: (in thousands) Year ended Year ended Net loss $ (65,354 ) $ (55,238 ) Weighted-average common shares – basic and diluted 89,086 81,837 Net loss per share – basic and diluted $ (0.73 ) $ (0.67 ) The effect of any potential exercise of the Company’s stock options outstanding during the year ended December 31, 2021 December 31, 2020

Note 12 - Stock-based Compensat

Note 12 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	12. Stock based compensation: (a) Stock option plan and employee stock purchase plan Effective June 1, 2021, The New Incentive Plan authorizes the Board of Directors to administer the New Incentive Plan to provide equity‑based compensation in the form of stock options, stock appreciation rights., restricted stock, restricted stock units and Dividend Equivalents. The Corporation currently maintains its existing Share Option Plan and 2015 2015 June 1, 2021 no 2015 The aggregate number of our common shares, no may June 1, 2021, not not Under both the Share Option Plan and the New Incentive Plan, the exercise price of each option equals the closing trading price of the Company’s stock on the day prior to the grant if the grant is made during the trading day or the closing trading price on the day of grant if the grant is issued after markets have closed. Vesting is provided for at the discretion of the Board of Directors and the expiration of options is to be no The Company uses the fair value based method of accounting for employee awards granted under both plans. The Company calculates the fair value of each stock option grant using the Black‑Scholes option pricing model at the grant date. The stock‑based compensation cost of the options is recognized as stock‑based compensation expense over the relevant vesting period of the stock options using an estimate of the number of options that will eventually vest. The ESPP, which will be administered by the Board of Directors, allows eligible employees of the Company with an opportunity to purchase Common Shares through accumulated payroll deductions up to a maximum 15% first February 1 August 1 85% The maximum number of Common Shares which will be made available for sale under the ESPP will be 1,700,000 Common Shares. The Company has not first December 31, 2021. Stock option transactions for the year ended December 31, 2021 December 31, 2020, Option numbers are in (000 s) Weighted average Options Weighted average exercise price remaining contractual life (years) Aggregate Intrinsic Value Outstanding, December 31, 2019 5,941 $ 2.84 Granted 6,362 6.81 Exercised (235 ) 2.45 Forfeited (126 ) 4.50 Outstanding, December 31, 2020 11,942 $ 4.97 Granted 4,659 3.84 Exercised (82 ) 2.32 Forfeited (1,407 ) 5.38 Outstanding, December 31, 2021 15,112 $ 4.61 6.6 $ 96,117 Exercisable, December 31, 2021 8,164 $ 4.50 5.3 $ 96,117 Vested and expected to vest, December 31, 2021 14,068 $ 4.60 6.5 $ 96,117 Aggregate intrinsic value represents the excess of the value of the closing stock price on the previous trading day of the respective balance sheet dates over the exercise price of the stock options. Total intrinsic value of options exercised was $222 thousand for 2021 2020 As of December 31, 2021, The following table presents the weighted average assumptions that were used in the Black‑Scholes option pricing model to determine the fair value of stock options granted during the period, and the resultant weighted average fair values: Year ended December 31, 2021 Year ended December 31, 2020 Risk-free interest rate 0.59 % 1.27 % Expected dividend yield - - Expected volatility 81.8 % 85.9 % Expected life of options (years) 5 5 Grant date fair value $ 2.47 $ 4.59 The Company uses historical data to estimate the expected dividend yield and expected volatility of its common shares in determining the fair value of stock options. The expected life of the options represents the estimated length of time the options are expected to remain outstanding. The following table presents the vesting terms of options granted in the period: Option numbers are in (000 s) Year ended Year ended Number of options Number of options Cliff vesting after one year anniversary - 300 3 year vesting ( 50% 25% 25% 430 862 4 year vesting ( 50% 16 2/3% 16 2/3% 16 2/3% 3,429 5,200 Earlier of Performance criteria or 4 years 800 - Total stock options granted in the year 4,659 6,362 During the year ended December 31, 2021, one no December 31, 2021, During the year ended December 31, 2021, two not fourth November 11, 2021, (b) Restricted share units The Company has a stock incentive plan (SIP) pursuant to which the Board may one December 31, 2021 2020 Year ended, December 31, 2021 Year ended, December 31, 2020 Number (in thousands) Weighted average grant date fair value Number (in thousands) Weighted average grant date fair value Outstanding, beginning of period - $ - 40 $ 2.00 Granted - - 645 7.32 Vested - - (685 ) 7.01 Outstanding, end of period - $ - - $ - On March 10, 2020, three May 5, 2020, three four July 10, 2020, On June 3, 2019, three one May 5, 2020, one one one July 2, 2020, The grant date fair value of the RSUs was determined as the closing value of the common shares of the Company on the Nasdaq Stock Market on the date prior to the date of grant. (c) Share-based payment expense The Company recorded share-based payment expense related to stock options and RSUs as follows: Year ended Year ended Research and development $ 3,789 $ 3,720 General and administrative 9,160 17,718 Total $ 12,949 $ 21,438

Note 13 - Collaborative Agreeme

Note 13 - Collaborative Agreements	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Collaborative Agreements [Text Block]	13. Collaborative agreements: The Company enters into research, development and license agreements in the ordinary course of business where the Company receives research services and rights to proprietary technologies. Milestone and royalty payments that may On November 4, 2021, HM43239. five 5 Under the Company’s license agreement with Hanmi, the Company has maximum obligations for clinical development and global regulatory milestones totaling $64.5 million for the first HM43239, second third may not Under the Company’s license agreement with CrystalGenomics for rights to CG- 806, 2 may not On June 13, 2018, 806 2 may not On March 7, 2018, 581, two

Note 14 - Income Taxes

Note 14 - Income Taxes	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	14. Income taxes: (a) Income taxes For the years ended December 31, 2021 2020, December 31, 2021 December 31, 2020 Loss attributed to US foreign operations $ (52,447 ) $ (39,757 ) Loss attributed to Canadian operations (12,907 ) (15,481 ) Income (loss) before income taxes $ (65,354 ) $ (55,238 ) (b) Tax rate reconciliation Major items causing the Company’s income tax rate to differ from the statutory rate of approximately 26.5% ( December 31, 2020 Year ended Year ended Net loss $ (65,354 ) $ (55,238 ) Statutory Canadian corporate tax rate 26.5 % 26.5 % Computed expected tax recovery $ (17,319 ) $ (14,638 ) Non-deductible permanent differences 3,707 4,959 Change in valuation allowance 15,274 10,383 Foreign tax rate differential (683 ) (428 ) Prior year true-up adjustments (951 ) (230 ) Other (28 ) (46 ) $ - $ - (c) Significant components of deferred taxes The tax effects of temporary differences that give rise to significant portions of the unrecognized deferred tax assets are presented below: December 31, 2021 December 31, 2020 Net operating losses carried forward $ 49,286 $ 37,362 Research and development expenditures 5,032 5,032 Property, equipment, and other intangible assets 7,261 3,760 Research and development tax credits 4,202 3,597 Financing costs 1,580 2,336 Right-of-use assets 40 40 Total deferred tax assets 67,401 52,127 Valuation allowance (67,401 ) (52,127 ) Net deferred tax asset $ - $ - The valuation allowance at December 31, 2021 not not not not not not The Company has Canadian undeducted research and development expenditures, totaling $19.0 million that can be carried forward indefinitely. The Company also has Canadian non‑refundable federal and provincial investment tax credits of approximately $3.3 million which are available to reduce future federal taxes payable and begin to expire in 2022, 2038. In addition, the Company has Canadian non-capital loss carryforwards of $177.9 million. To the extent that the non-capital loss carryforwards are not 2026. not 2034. The Company files income tax returns with Canada and its provinces and territories. Generally, we are subject to routine examinations by the Canada Revenue Agency ("CRA"). Income tax returns filed with various provincial jurisdictions are generally open to examination for periods of four five The Company also files income tax returns for our U.S. operations and subsidiary with the U.S. federal and state tax jurisdictions. Generally, we are subject to routine examination by taxing authorities in the U.S. jurisdictions. There are presently no

Note 15 - Selected Quarterly Fi

Note 15 - Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Quarterly Financial Information [Text Block]	15. Selected quarterly financial data (unaudited): Selected financial data (unaudited) for the periods presented was as follows: March 31, 2021 June 30, 2021 September 30, 2021 December 31, 2021 Revenue $ - $ - $ - $ - Net loss (16,227 ) (13,470 ) (11,333 ) (24,324 ) Basic and diluted loss per common share (0.18 ) (0.15 ) (0.13 ) (0.27 ) March 31, 2020 June 30, 2020 September 30, 2020 December 31, 2020 Revenue $ - $ - $ - $ - Net loss (11,526 ) (15,750 ) (13,249 ) (14,713 ) Basic and diluted loss per common share (0.15 ) (0.21 ) (0.15 ) (0.17 )

Note 16 - Subsequent Events

Note 16 - Subsequent Events	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	16. Subsequent events Subsequent to the year end, the Company issued 3,870,000 stock options to directors, officers, employees and consultants with an average exercise price of $1.34. The stock options vest 50% after one three one two

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	(a) Basis of consolidation: These consolidated financial statements include the accounts of its subsidiaries. All intercompany transactions, balances, revenue and expenses are eliminated on consolidation.
Basis of Accounting, Policy [Policy Text Block]	(b) Basis of presentation: These consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States, or GAAP and the rules and regulations of the Securities and Exchange Commission, or SEC, related to annual reports filed on Form 10
Use of Estimates, Policy [Policy Text Block]	(c) Significant accounting policies, estimates and judgments: The preparation of the consolidated financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of revenue and expenses during the reporting period. Actual outcomes could differ from those estimates. The consolidated financial statements include estimates, which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements and may The estimates and underlying assumptions are reviewed on a regular basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected.
Lessee, Leases [Policy Text Block]	(d) Leases The Company’s operating leases of tangible property with terms greater than twelve
Cash and Cash Equivalents, Policy [Policy Text Block]	(e) Cash and cash equivalents: Cash and cash equivalents are short-term highly liquid investments with original maturities of 90
Investment, Policy [Policy Text Block]	(f) Investments: Investments consist of term deposits with original maturities greater than 90
Concentration Risk, Credit Risk, Policy [Policy Text Block]	(g) Concentration of risk: The Company is subject to credit risk from the Company’s cash and cash equivalents and investments. The carrying amount of the financial assets represents the maximum credit exposure. The Company manages credit risk associated with its cash and cash equivalents and investments by maintaining minimum standards of R1‑low
Property, Plant and Equipment, Policy [Policy Text Block]	(h) Property and equipment: Property and equipment is measured at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. The Company records depreciation at rates that charge operations with the cost of the assets over their estimated useful lives on a straight‑line basis as follows: Office furniture 5 years Laboratory equipment 5 years Computer hardware 3 years Computer software 3 years Leasehold improvements Life of lease The residual value, useful life and methods of depreciation of the assets are reviewed at each reporting period and adjusted prospectively if appropriate.
Research and Development Expense, Policy [Policy Text Block]	(i) Research and development: Research and development (R&D) costs are expensed as incurred. R&D costs consist primarily of salaries and benefits, stock-based compensation, manufacturing, contract services, clinical trials and research related overhead. Non-refundable advance payments for goods and services that will be used in future research are recorded in prepaid and other assets and are expensed when the services are performed. The Company records expenses for research and development activities based on Management’s estimates of services received and efforts expended pursuant to contracts with vendors that conduct research and development on the Company’s behalf. The financial terms vary from contract to contract and may
Fair Value Measurement, Policy [Policy Text Block]	(j) Fair value: The Company measures its financial assets and liabilities at fair value. The carrying amounts for the Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
Share-based Payment Arrangement [Policy Text Block]	(k) Stock-based compensation: The Company has a stock‑based compensation plan (the “Plan”) available to officers, directors, employees and consultants with grants under the Plan approved by the Company’s Board of Directors. Under the Plan, the exercise price of each option equals the closing trading price of the Company’s stock on the day prior to the grant if the grant is made during the trading day or the closing trading price on the day of grant if the grant is issued after markets have closed. Vesting is provided for at the discretion of the Board of Directors and the expiration of options is to be no 10 The Company uses the fair value based method of accounting for employee awards granted under the Plan. The Company calculates the fair value of each stock option grant using the Black‑Scholes option pricing model at the grant date. The stock‑based compensation cost of the options is recognized as stock‑based compensation expense over the relevant vesting period of the stock options using an estimate of the number of options that will eventually vest. Stock options awarded to non‑employees are measured at grant-date fair value of the equity instruments issued in accordance with FASB issued accounting standards update No 2018 07, 718. The Company has a stock incentive plan pursuant to which the Board may
Segment Reporting, Policy [Policy Text Block]	(l) Segment reporting: Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, or CODM. The Company’s Chief Executive Officer serves as its CODM. The Company views its operations and manages its business as one segment, which is the discovery and development of personalized therapies addressing unmet medical needs in oncology. The Company operates primarily in the US.
Earnings Per Share, Policy [Policy Text Block]	(m) Loss per share: Basic loss per share is computed by dividing the net loss available to common shareholders by the weighted average number of shares outstanding during the year. Diluted loss per share is computed similarly to basic loss per share except that the weighted average share outstanding is increased to include additional shares for the assumed exercise of stock options and warrants, if dilutive. The number of additional shares is calculated by assuming that outstanding stock options and warrants were exercised and that the proceeds from such exercises were used to acquire common stock at the average market price during the year. The inclusion of the Company’s stock options and warrants in the computation of diluted loss per share has an anti‑dilutive effect on the loss per share and, therefore, they have been excluded from the calculation of diluted loss per share.
Income Tax, Policy [Policy Text Block]	(n) Income taxes: The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary differences are expected to be recovered or settled. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. Reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely than not December 31, 2021 December 31, 2020, not not

Note 2 - Significant Accounti_2

Note 2 - Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Property, Plant and Equipment, Useful Life [Table Text Block]	Office furniture 5 years Laboratory equipment 5 years Computer hardware 3 years Computer software 3 years Leasehold improvements Life of lease

Note 4 - Prepaid Expenses (Tabl

Note 4 - Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	December 31, December 31, 2021 2020 Prepaid research and development expenses $ 632 $ 622 Other prepaid expenses 1,844 1,932 $ 2,476 $ 2,554

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, 2021 Cost Accumulated depreciation Net book value Laboratory equipment $ 369 $ 188 $ 181 Computer hardware 198 144 54 Computer software 222 222 - Office furniture 140 95 45 Leasehold improvements 184 141 43 $ 1,113 $ 790 $ 323 December 31, 2020 Cost Accumulated depreciation Net book value Laboratory equipment $ 185 $ 177 $ 8 Computer hardware 170 99 71 Computer software 222 174 48 Office furniture 140 72 68 Leasehold improvements 184 118 66 $ 901 $ 640 $ 261

Note 6 - Right-of-use Assets,_2

Note 6 - Right-of-use Assets, Operating Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Right-of-use Assets [Table Text Block]	Year ended Year ended Right-of-use assets, beginning of year $ 1,848 $ 1,837 Additions to right-of-use assets 12 11 Right-of-use assets, end of year 1,860 1,848 Accumulated amortization (1,395 ) (923 ) Right-of use assets, NBV $ 465 $ 925

Note 7 - Investments (Tables)

Note 7 - Investments (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Investment [Table Text Block]	December 31, 2021 Cost Unrealized gain Market value Guaranteed Investment Certificate $ 20,016 - 20,016 Commercial notes 19,998 19,998 $ 40,014 - 40,014 December 31, 2020 Cost Unrealized gain Market value United States Treasury Bills $ 5,000 - 5,000 $ 5,000 - 5,000

Note 8 - Fair Value Measureme_2

Note 8 - Fair Value Measurements and Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	December 31, 2021 Level 1 Level 2 Level 3 Assets Money Market accounts $ 17,974 $ - $ 17,974 $ - Money Market Funds 15,801 - 15,801 - High interest savings accounts 5,045 - 5,045 - Commercial notes 19,998 - 19,998 - Guaranteed Investment Certificate 20,016 20,016 $ 78,834 $ - $ 78,834 $ - December 31, 2020 Level 1 Level 2 Level 3 Assets Money Market accounts $ 668 $ - $ 668 $ - Money Market Funds 44,000 - 44,000 - High interest savings accounts 48,397 - 48,397 - United States Treasury Bill 5,000 - 5,000 - Government of Canada Treasury Bill 23,999 - 23,999 - $ 122,064 $ - $ 122,064 $ -

Note 9 - Accrued Liabilities (T

Note 9 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, December 31, 2021 2020 Accrued personnel related costs $ 2,152 $ 1,917 Accrued research and development expenses 3,520 1,932 Other accrued expenses 344 253 $ 6,016 $ 4,102

Note 10 - Lease Liability (Tabl

Note 10 - Lease Liability (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Years ending December 31, 2022 $ 470 2023 123 Thereafter - $ 593
Lessee, Operating Lease Liability and Weighted Average [Table Text Block]	December 31, December 31, 2021 2020 Weighted-average remaining term – operating leases (years) 1.2 2.1 Weighted-average discount rate – operating leases 5.37 % 5.40 % Lease liability, current portion $ 459 $ 539 Lease liability, long term portion 115 535 Lease liability, total $ 574 $ 1,074
Lease, Cost [Table Text Block]	Year ended December 31, 2021 Year ended December 31, 2020 Operating lease cost $ 515 $ 530 Operating cash flows from operating leases $ 555 $ 537

Note 11 - Share Capital (Tables

Note 11 - Share Capital (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	(in thousands) Year ended Year ended Net loss $ (65,354 ) $ (55,238 ) Weighted-average common shares – basic and diluted 89,086 81,837 Net loss per share – basic and diluted $ (0.73 ) $ (0.67 )

Note 12 - Stock-based Compens_2

Note 12 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Option numbers are in (000 s) Weighted average Options Weighted average exercise price remaining contractual life (years) Aggregate Intrinsic Value Outstanding, December 31, 2019 5,941 $ 2.84 Granted 6,362 6.81 Exercised (235 ) 2.45 Forfeited (126 ) 4.50 Outstanding, December 31, 2020 11,942 $ 4.97 Granted 4,659 3.84 Exercised (82 ) 2.32 Forfeited (1,407 ) 5.38 Outstanding, December 31, 2021 15,112 $ 4.61 6.6 $ 96,117 Exercisable, December 31, 2021 8,164 $ 4.50 5.3 $ 96,117 Vested and expected to vest, December 31, 2021 14,068 $ 4.60 6.5 $ 96,117
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year ended December 31, 2021 Year ended December 31, 2020 Risk-free interest rate 0.59 % 1.27 % Expected dividend yield - - Expected volatility 81.8 % 85.9 % Expected life of options (years) 5 5 Grant date fair value $ 2.47 $ 4.59
Schedule of Share-based Payment Award, Options, Grants in Period [Table Text Block]	Option numbers are in (000 s) Year ended Year ended Number of options Number of options Cliff vesting after one year anniversary - 300 3 year vesting ( 50% 25% 25% 430 862 4 year vesting ( 50% 16 2/3% 16 2/3% 16 2/3% 3,429 5,200 Earlier of Performance criteria or 4 years 800 - Total stock options granted in the year 4,659 6,362
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Year ended, December 31, 2021 Year ended, December 31, 2020 Number (in thousands) Weighted average grant date fair value Number (in thousands) Weighted average grant date fair value Outstanding, beginning of period - $ - 40 $ 2.00 Granted - - 645 7.32 Vested - - (685 ) 7.01 Outstanding, end of period - $ - - $ -
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year ended Year ended Research and development $ 3,789 $ 3,720 General and administrative 9,160 17,718 Total $ 12,949 $ 21,438

Note 14 - Income Taxes (Tables)

Note 14 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	December 31, 2021 December 31, 2020 Loss attributed to US foreign operations $ (52,447 ) $ (39,757 ) Loss attributed to Canadian operations (12,907 ) (15,481 ) Income (loss) before income taxes $ (65,354 ) $ (55,238 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year ended Year ended Net loss $ (65,354 ) $ (55,238 ) Statutory Canadian corporate tax rate 26.5 % 26.5 % Computed expected tax recovery $ (17,319 ) $ (14,638 ) Non-deductible permanent differences 3,707 4,959 Change in valuation allowance 15,274 10,383 Foreign tax rate differential (683 ) (428 ) Prior year true-up adjustments (951 ) (230 ) Other (28 ) (46 ) $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2021 December 31, 2020 Net operating losses carried forward $ 49,286 $ 37,362 Research and development expenditures 5,032 5,032 Property, equipment, and other intangible assets 7,261 3,760 Research and development tax credits 4,202 3,597 Financing costs 1,580 2,336 Right-of-use assets 40 40 Total deferred tax assets 67,401 52,127 Valuation allowance (67,401 ) (52,127 ) Net deferred tax asset $ - $ -

Note 15 - Selected Quarterly _2

Note 15 - Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Quarterly Financial Information [Table Text Block]	March 31, 2021 June 30, 2021 September 30, 2021 December 31, 2021 Revenue $ - $ - $ - $ - Net loss (16,227 ) (13,470 ) (11,333 ) (24,324 ) Basic and diluted loss per common share (0.18 ) (0.15 ) (0.13 ) (0.27 ) March 31, 2020 June 30, 2020 September 30, 2020 December 31, 2020 Revenue $ - $ - $ - $ - Net loss (11,526 ) (15,750 ) (13,249 ) (14,713 ) Basic and diluted loss per common share (0.15 ) (0.21 ) (0.15 ) (0.17 )

Note 2 - Significant Accounti_3

Note 2 - Significant Accounting Policies (Details Textual)	12 Months Ended
	Dec. 31, 2021
Number of Operating Segments	1

Note 2 - Significant Accounti_4

Note 2 - Significant Accounting Policies - Property, Plant and Equipment Useful Life (Details)	12 Months Ended
	Dec. 31, 2021
Furniture and Fixtures [Member]
Property, plant and equipment, useful life (Year)	5 years
Laboratory Equipment [Member]
Property, plant and equipment, useful life (Year)	5 years
Computer Equipment [Member]
Property, plant and equipment, useful life (Year)	3 years
Software and Software Development Costs [Member]
Property, plant and equipment, useful life (Year)	3 years

Note 3 - Cash and Cash Equiva_2

Note 3 - Cash and Cash Equivalents (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Cash, Ending Balance	$ 294	$ 329
Cash Equivalents, at Carrying Value, Total	$ 38,820	$ 117,064

Note 4 - Prepaid Expenses - Pre

Note 4 - Prepaid Expenses - Prepaid Expenses and Other Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Prepaid research and development expenses	$ 632	$ 622
Other prepaid expenses	1,844	1,932
Prepaid Expense, Current, Total	$ 2,476	$ 2,554

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, plant and equipment, gross	$ 1,113	$ 901
Accumulated depreciation	790	640
Property, plant and equipment, net	323	261
Laboratory Equipment [Member]
Property, plant and equipment, gross	369	185
Accumulated depreciation	188	177
Property, plant and equipment, net	181	8
Computer Equipment [Member]
Property, plant and equipment, gross	198	170
Accumulated depreciation	144	99
Property, plant and equipment, net	54	71
Software and Software Development Costs [Member]
Property, plant and equipment, gross	222	222
Accumulated depreciation	222	174
Property, plant and equipment, net	0	48
Furniture and Fixtures [Member]
Property, plant and equipment, gross	140	140
Accumulated depreciation	95	72
Property, plant and equipment, net	45	68
Leasehold Improvements [Member]
Property, plant and equipment, gross	184	184
Accumulated depreciation	141	118
Property, plant and equipment, net	$ 43	$ 66

Note 6 - Right-of-use Assets,_3

Note 6 - Right-of-use Assets, Operating Leases - Schedule of Right-of-use Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Right-of-use assets, beginning of year	$ 1,848	$ 1,837
Additions to right-of-use assets	12	11
Right-of-use assets, end of year	1,860	1,848
Accumulated amortization	(1,395)	(923)
Right-of use assets, NBV	$ 465	$ 925

Note 7 - Investments - Investme

Note 7 - Investments - Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Investment, Cost	$ 40,014	$ 5,000
Investment, Unrealized gain/(loss)	0	0
Investment, Market value	40,014	5,000
Guaranteed Investment Certificate [Member]
Investment, Cost	20,016
Investment, Unrealized gain/(loss)	0
Investment, Market value	20,016
US Treasury Securities [Member]
Investment, Cost		5,000
Investment, Unrealized gain/(loss)		0
Investment, Market value		$ 5,000
Commercial Notes [Member]
Investment, Cost	19,998
Investment, Unrealized gain/(loss)
Investment, Market value	$ 19,998

Note 8 - Fair Value Measureme_3

Note 8 - Fair Value Measurements and Financial Instruments - Assets Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Assets, fair value	$ 78,834	$ 122,064
Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0	0
Fair Value, Inputs, Level 2 [Member]
Assets, fair value	78,834	122,064
Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Money Market Accounts [Member]
Assets, fair value	17,974	668
Money Market Accounts [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0	0
Money Market Accounts [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	17,974	668
Money Market Accounts [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Money Market Funds [Member]
Assets, fair value	15,801	44,000
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0	0
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	15,801	44,000
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Bank Time Deposits [Member]
Assets, fair value	5,045	48,397
Bank Time Deposits [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0	0
Bank Time Deposits [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	5,045	48,397
Bank Time Deposits [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Commercial Notes [Member]
Assets, fair value	19,998
Commercial Notes [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0
Commercial Notes [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	19,998
Commercial Notes [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0
US Treasury Securities [Member]
Assets, fair value		5,000
US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value		0
US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value		5,000
US Treasury Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value		0
Corporate Debt Securities [Member]
Assets, fair value	20,016
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	20,016
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value
Canadian Treasury Securities [Member]
Assets, fair value		23,999
Canadian Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value		0
Canadian Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value		23,999
Canadian Treasury Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value		$ 0

Note 9 - Accrued Liabilities -

Note 9 - Accrued Liabilities - Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accrued personnel related costs	$ 2,152	$ 1,917
Accrued research and development expenses	3,520	1,932
Other accrued expenses	344	253
Accrued Liabilities, Current, Total	$ 6,016	$ 4,102

Note 10 - Lease Liability (Deta

Note 10 - Lease Liability (Details Textual)	Dec. 31, 2021
Lessee, Operating Lease, Renewal Term (Year)	5 years

Note 10 - Lease Liability - Sch

Note 10 - Lease Liability - Schedule of Minimum Payments Under Operating Leases (Details) $ in Thousands	Dec. 31, 2021USD ($)
2022	$ 470
2023	123
Thereafter	0
Lessee, Operating Lease, Liability, to be Paid, Total	$ 593

Note 10 - Lease Liability - Lea

Note 10 - Lease Liability - Lease Liability (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Weighted-average remaining term – operating leases (years) (Year)	1 year 2 months 12 days	2 years 1 month 6 days
Weighted-average discount rate – operating leases	5.37%	5.40%
Lease liability, current portion	$ 459	$ 539
Lease liability, long term portion	115	535
Lease liability, total	$ 574	$ 1,074

Note 10 - Lease Liability - Ope

Note 10 - Lease Liability - Operating Lease Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating lease cost	$ 515	$ 530
Operating cash flows from operating leases	$ 555	$ 537

Note 11 - Share Capital (Detail

Note 11 - Share Capital (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Dec. 14, 2021	Nov. 04, 2021	Aug. 10, 2020	Dec. 31, 2021	Dec. 31, 2020	May 05, 2020
Stock Issued During Period, Value, Licensing Fee				$ 7,500
The 2020 ATM Offering [Member]
Stock Issuance Program, Authorized Amount						$ 75,000
Stock Issued During Period, Shares, New Issues (in shares)				15,315
Shares Issued, Price Per Share (in dollars per share)				$ 2.446
Proceeds from Issuance of Common Stock, Gross				$ 37
Proceeds from Issuance of Common Stock				$ 36	$ 0
Stock Issuance, Percent of Cash Commission to Broker				3.00%
July 2020 Confidentially Marketed Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)			11,854,472
Shares Issued, Price Per Share (in dollars per share)			$ 5.25
Proceeds from Issuance of Common Stock, Gross			$ 62,236
Stock Issuance, Percent of Cash Commission to Broker			6.00%
Proceeds from Issuance of Common Stock, Net of Share Issuance Costs			$ 58,234
HM43239 [Member]
Stock Issued During Period, Shares, Licensing Fees (in shares)	3,235,548	3,235,548
Stock Issued During Period, Value, Licensing Fee	$ 7,500	$ 7,500

Note 11 - Share Capital - Loss

Note 11 - Share Capital - Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Net loss	$ (24,324)	$ (11,333)	$ (13,470)	$ (16,227)	$ (14,713)	$ (13,249)	$ (15,750)	$ (11,526)	$ (65,354)	$ (55,238)
Weighted-average common shares – basic and diluted (in shares)									89,086	81,837
Net loss per share – basic and diluted (in dollars per share)	$ (0.27)	$ (0.13)	$ (0.15)	$ (0.18)	$ (0.17)	$ (0.15)	$ (0.21)	$ (0.15)	$ (0.73)	$ (0.67)

Note 12 - Stock-based Compens_3

Note 12 - Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jul. 10, 2020	Jul. 02, 2020	May 05, 2020	Mar. 10, 2020	Jun. 03, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Nov. 11, 2021	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares (in shares)						6,343,242
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)						10 years
Employee Stock Purchase Plan, Maximum Payroll Deduction, Percent						15.00%
Employee Stock Purchase Plan, Stock Purchase Price, Percent						85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)						15,112,000	11,942,000			5,941,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value						$ 222	$ 850
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount						$ 6,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						1 year 8 months 4 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)						8,164,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in dollars per share)						$ 4.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Month)						5 years 3 months 18 days
Share-based Payment Arrangement, Expense						$ 12,949	$ 21,438
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						4,659,000	6,362,000	6,362,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in shares)						14,068,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		40,000		645,000	80,000	0	645,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)			4 months	3 months
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total (in shares)	645,000
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)					40,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)					3 months
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)			13 months		1 year
Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)						1,679,169
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Month)						12 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term (Month)						12 months
Officer [Member] | Continuing Vesting Options with No Service Requirement [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number (in shares)						504,833
Officer [Member] | Vested Options [Member]
Share-based Payment Arrangement, Expense						$ 945
Officer [Member] | Unvested Options [Member]
Share-based Payment Arrangement, Expense						$ 663
Officer [Member] | Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						800,000
Officer [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in dollars per share)						$ 1.03
Officer [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in dollars per share)						$ 7.44
Officer One [Member] | Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						400,000
Officer One [Member] | Performance Shares [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in shares)						200,000			200,000
Officer One [Member] | Performance Shares [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in shares)						200,000
Officer Two [Member] | Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						400,000
Officer Two [Member] | Performance Shares [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in shares)						200,000
Officer Two [Member] | Performance Shares [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in shares)						200,000
ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)						1,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)						0

Note 12 - Stock-based Compens_4

Note 12 - Stock-based Compensation - Stock Option Transactions (Details) - USD ($) $ / shares in Units, shares in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Outstanding, options (in shares)	11,942		5,941
Outstanding, weighted average exercise price (in dollars per share)	$ 4.97		$ 2.84
Granted, options (in shares)	4,659	6,362	6,362
Granted, weighted average exercise price (in dollars per share)	$ 3.84		$ 6.81
Exercised, options (in shares)	(82)		(235)
Exercised, weighted average exercise price (in dollars per share)	$ 2.32		$ 2.45
Forfeited, options (in shares)	(1,407)	(126)
Forfeited, weighted average exercise price (in dollars per share)	$ 5.38	$ 4.50
Outstanding, options (in shares)	15,112	11,942
Outstanding, weighted average exercise price (in dollars per share)	$ 4.61	$ 4.97
Outstanding, weighted average remaining contractual life (Year)	6 years 7 months 6 days
Outstanding, aggregate intrinsic value	$ 96,117
Exercisable, options (in shares)	8,164
Exercisable, weighted average exercise price (in dollars per share)	$ 4.50
Exercisable, weighted average remaining contractual life (Year)	5 years 3 months 18 days
Exercisable, aggregate intrinsic value	$ 96,117
Vested and expected to vest, options (in shares)	14,068
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 4.60
Vested and expected to vest, weighted average remaining contractual life (Year)	6 years 6 months
Vested and expected to vest, aggregate intrinsic value	$ 96,117

Note 12 - Stock-based Compens_5

Note 12 - Stock-based Compensation - Weighted Average Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Risk-free interest rate	0.59%	1.27%
Expected dividend yield	0.00%	0.00%
Expected volatility	81.80%	85.90%
Expected life of options (Year)	5 years	5 years
Grant date fair value (in dollars per share)	$ 2.47	$ 4.59

Note 12 - Stock-based Compens_6

Note 12 - Stock-based Compensation - Vesting Terms of Options Granted (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Stock options granted in the period (in shares)	4,659	6,362	6,362
Options with Cliff Vesting After One Year Anniversary [Member]
Stock options granted in the period (in shares)	0	300
Options with Three Year Vesting [Member]
Stock options granted in the period (in shares)	430	862
Options with Four Year Vesting [Member]
Stock options granted in the period (in shares)	3,429	5,200
Options With Performance Criteria [Member]
Stock options granted in the period (in shares)	800	0

Note 12 - Stock-based Compens_7

Note 12 - Stock-based Compensation - Vesting Terms of Options Granted (Details) (Parentheticals)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Options with Three Year Vesting [Member] | Share-based Payment Arrangement, Tranche One [Member]
Vesting percentage	50.00%	50.00%
Options with Three Year Vesting [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Vesting percentage	25.00%	25.00%
Options with Three Year Vesting [Member] | Share-based Payment Arrangement, Tranche Three [Member]
Vesting percentage	25.00%	25.00%
Options with Four Year Vesting [Member] | Share-based Payment Arrangement, Tranche One [Member]
Vesting percentage	50.00%	50.00%
Options with Four Year Vesting [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Vesting percentage	16.67%	16.67%
Options with Four Year Vesting [Member] | Share-based Payment Arrangement, Tranche Three [Member]
Vesting percentage	16.67%	16.67%
Options with Four Year Vesting [Member] | Share-based Payment Arrangement, Tranche Four [Member]
Vesting percentage	16.67%	16.67%

Note 12 - Stock-based Compens_8

Note 12 - Stock-based Compensation - Restricted Stock Units (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	Jul. 02, 2020	Mar. 10, 2020	Jun. 03, 2019	Dec. 31, 2021	Dec. 31, 2020
Outstanding, beginning of period (in shares)				0	40,000
Outstanding, beginning of period, weighted average grant date fair value (in dollars per share)				$ 0	$ 2
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	40,000	645,000	80,000	0	645,000
Granted, weighted average grant date fair value (in dollars per share)				$ 0	$ 7.32
Vested (in shares)				0	(685,000)
Vested, weighted average grant date fair value (in dollars per share)				$ 0	$ 7.01
Outstanding, end of period (in shares)				0	0
Outstanding, end of period, weighted average grant date fair value (in dollars per share)				$ 0	$ 0

Note 12 - Stock-based Compens_9

Note 12 - Stock-based Compensation - Share-based Payment Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based payment expense	$ 12,949	$ 21,438
Research and Development Expense [Member]
Share-based payment expense	3,789	3,720
General and Administrative Expense [Member]
Share-based payment expense	$ 9,160	$ 17,718

Note 13 - Collaborative Agree_2

Note 13 - Collaborative Agreements (Details Textual) - USD ($) $ in Millions	Dec. 14, 2021	Nov. 04, 2021	Dec. 31, 2021	Jun. 13, 2018	Mar. 07, 2018
Stock Issued During Period, Value, Licensing Fee			$ 7.5
CrystalGenomics [Member]
Collaborative Agreement, Milestone Payment			16
Collaborative Agreement, Regulatory Milestone			$ 44
Ohm Oncology [Member]
Collaborative Agreements, Potential Additional Milestone Payments Receivable					$ 125
HM43239 [Member]
License Fee, Total		$ 12.5
Payments for License Fee		5
Stock Issued During Period, Value, Licensing Fee	$ 7.5	$ 7.5
Stock Issued During Period, Shares, Licensing Fees (in shares)	3,235,548	3,235,548
Clinical Development and Global Regulatory Milestone, First Indication		$ 64.5
Clinical Development and Global Regulatory Milestone, Second Indication		34
Clinical Development and Global Regulatory Milestone, Third Indication		29
Global Sales Milestone		$ 280
Exclusive License to CG806 in China, Development Milestones [Member] | CrystalGenomics [Member]
Collaborative Agreement, Regulatory Milestone				$ 6
Exclusive License to CG806 in China, Regulatory Milestones [Member] | CrystalGenomics [Member]
Collaborative Agreement, Regulatory Milestone				$ 20

Note 14 - Income Taxes (Details

Note 14 - Income Taxes (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	26.50%	26.50%
Foreign Tax Authority [Member] | Canada Revenue Agency [Member]
Operating Loss Carryforwards, Total	$ 177.9
Foreign Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total	0.9
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	19
Investment Tax Credit Carryforward [Member] | Foreign Tax Authority [Member] | Canada Revenue Agency [Member]
Tax Credit Carryforward, Amount	3.3
Investment Tax Credit Carryforward [Member] | Domestic Tax Authority [Member] | Canada Revenue Agency [Member]
Tax Credit Carryforward, Amount	$ 1.8

Note 14 - Income Taxes - Net Lo

Note 14 - Income Taxes - Net Loss (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Loss attributed to US foreign operations									$ (52,447)	$ (39,757)
Loss attributed to Canadian operations									(12,907)	(15,481)
Net loss	$ (24,324)	$ (11,333)	$ (13,470)	$ (16,227)	$ (14,713)	$ (13,249)	$ (15,750)	$ (11,526)	$ (65,354)	$ (55,238)

Note 14 - Income Taxes - Provis

Note 14 - Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Net loss	$ (24,324)	$ (11,333)	$ (13,470)	$ (16,227)	$ (14,713)	$ (13,249)	$ (15,750)	$ (11,526)	$ (65,354)	$ (55,238)
Statutory Canadian corporate tax rate									26.50%	26.50%
Computed expected tax recovery									$ (17,319)	$ (14,638)
Non-deductible permanent differences									3,707	4,959
Change in valuation allowance									15,274	10,383
Foreign tax rate differential									(683)	(428)
Prior year true-up adjustments									(951)	(230)
Other									$ (28)	$ (46)

Note 14 - Income Taxes - Deferr

Note 14 - Income Taxes - Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Net operating losses carried forward	$ 49,286	$ 37,362
Research and development expenditures	5,032	5,032
Property, equipment, and other intangible assets	7,261	3,760
Research and development tax credits	4,202	3,597
Financing costs	1,580	2,336
Right-of-use assets	40	40
Total deferred tax assets	67,401	52,127
Valuation allowance	(67,401)	(52,127)
Net deferred tax asset	$ 0	$ 0

Note 15 - Selected Quarterly _3

Note 15 - Selected Quarterly Financial Data (Unaudited) - Quarterly Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Revenue	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Net loss	$ (24,324)	$ (11,333)	$ (13,470)	$ (16,227)	$ (14,713)	$ (13,249)	$ (15,750)	$ (11,526)	$ (65,354)	$ (55,238)
Basic and diluted loss per common share (in dollars per share)	$ (0.27)	$ (0.13)	$ (0.15)	$ (0.18)	$ (0.17)	$ (0.15)	$ (0.21)	$ (0.15)	$ (0.73)	$ (0.67)

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details Textual) - $ / shares	Jan. 01, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		4,659,000	6,362,000	6,362,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)		$ 3.84		$ 6.81
Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		3,429,000	5,200,000
Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		430,000	862,000
Share-based Payment Arrangement, Tranche One [Member] | Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		50.00%	50.00%
Share-based Payment Arrangement, Tranche One [Member] | Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		50.00%	50.00%
Share-based Payment Arrangement, Tranche Two [Member] | Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		16.67%	16.67%
Share-based Payment Arrangement, Tranche Two [Member] | Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%	25.00%
Share-based Payment Arrangement, Tranche Three [Member] | Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		16.67%	16.67%
Share-based Payment Arrangement, Tranche Three [Member] | Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%	25.00%
Share-based Payment Arrangement, Tranche Four [Member] | Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		16.67%	16.67%
Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	3,870,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)	$ 1.34
Subsequent Event [Member] | Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	425,000
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche One [Member] | Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	16.67%
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche Three [Member] | Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	16.67%
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche Three [Member] | Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
Subsequent Event [Member] | Share-based Payment Arrangement, Tranche Four [Member] | Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	16.67%